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2212-0661/© 2016 Published by Elsevier B.V. This is an opa b s t r a c ta r t i c l e i n f oKeywords: High throughput approaches such as whole genome sequencing (WGS) and whole exome sequencing (WES)
create an unprecedented amount of data providing powerful resources for clinical care and research. Recently,
WGS and WES services have been made available by commercial direct-to-consumer (DTC) companies. The
DTC offer of genetic testing (GT) has already brought attention to potentially problematic issues such as the ad-
equacy of consumers' informed consent and transparency of companies' research activities. In this study, we
analysed the websites of four DTC GT companies offering WGS and/or WES with regard to their policies
governing storage and future use of consumers' data and samples. The results are discussed in relation to recom-
mendations and guiding principles such as the “Statement of the European Society of HumanGenetics onDTC GT
for health-related purposes” (2010) and the “Framework for responsible sharing of genomic and health-related
data” (Global Alliance for Genomics and Health, 2014). The analysis reveals that some companies may store and
use consumers' samples or sequencing data for unspeciﬁed research and share the data with third parties. More-
over, the companies do not provide sufﬁcient or clear information to consumers about this,which can undermine
the validity of the consent process. Furthermore, while all companies state that they provide privacy safeguards
for data and mention the limitations of these, information about the possibility of re-identiﬁcation is lacking. Fi-
nally, although the companies that may conduct research do include information regarding proprietary claims
and commercialisation of the results, it is not clear whether consumers are aware of the consequences of these
policies. These results indicate that DTC GT companies still need to improve the transparency regarding handling
of consumers' samples and data, including having an explicit and clear consent process for research activities.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Whole-genome sequencing
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Consent1. Introduction
Direct-to-consumer (DTC) genetic testing (GT) companies operating
outside of the traditional healthcare system have attracted numerous
critiques of their practices over the last decade (Kalokairinou et al.,
2014). Beyond questioning the clinical validity and utility of the tests,
the appropriateness of medical supervision and genetic counselling,
some of the concerns centre on the storage and use of consumers' sam-
ples and data. These include a number of inter-related issues such as
what consumers are told (e.g., during the consent process) about stor-
age anduse of samples and data; proprietary claims stemming from sec-
ondary uses of sample and data; as well as the coupling of companies'
genetic testing offer with research activities. Indeed, an earlier explor-
ative study of DTC GT companies has shown that for some companies
the consent to participation in research may not be adequate; it
questioned whether the information provided by the companies about).
en access article under the CC BY-NCtheir research activities was clear and explicit enough for consumers
to understand what they were agreeing to (Howard et al., 2010). Fur-
thermore, it highlighted that such ambiguous presentations of informa-
tion for testing and research activities blur the lines between consumers
and research participants, undermine the informed choice of consumers
and may potentially undermine public trust in research in general
(Howard et al., 2015, 2010).
Recent advancements in sequencing technologies have resulted in a
signiﬁcant decrease in the price ofwhole-exome andwhole-genome se-
quencing (WES, WGS), which has allowed for a greater use of these ap-
proaches in both the clinical and research domains causing a shift in
testing approach from analysing one or a few genetic variants to the
study of an entire exome/genome sequence. WES/WGS generates an
unprecedented amount of sensitive health-related genomic data useful
in healthcare management and powerful in the research setting
(Rabbani et al., 2014). While much of the discussion surrounding the
ethical, legal and social implications (ELSI) of these high-throughput ap-
proaches has been focused on these settings, much less attention has
been paid to commercial companies offering sequencing services DTC.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ta
bl
e
1
In
fo
rm
at
io
n
on
th
e
co
m
pa
ni
es
,t
he
ir
W
ES
/W
G
S
se
rv
ic
es
,m
od
el
of
pr
ov
is
io
n
of
te
st
in
g,
an
d
th
e
w
eb
si
te
do
cu
m
en
ts
st
ud
ie
d.
Co
m
pa
ny
na
m
e
&
co
un
tr
y
D
es
cr
ip
ti
on
of
se
rv
ic
e
M
od
el
of
pr
ov
is
io
n
of
te
st
in
g
Se
ct
io
ns
of
th
e
w
eb
si
te
s
st
ud
ie
d
Ill
um
in
a,
U
SA
W
G
S:
Tr
uG
en
om
e
U
nd
ia
gn
os
ed
D
is
ea
se
Te
st
—
“i
nt
en
de
d
to
pr
ov
id
e
in
fo
rm
at
io
n
to
ph
ys
ic
ia
ns
to
ai
d
in
th
e
di
ag
no
si
s
of
in
he
ri
te
d
di
se
as
es
of
si
ng
le
-g
en
e
et
io
lo
gy
(M
en
de
lia
n
di
se
as
es
)”
.
Tr
uG
en
om
e
Pr
ed
is
po
si
ti
on
Sc
re
en
—
“a
na
ly
si
s
an
d
in
te
rp
re
ta
ti
on
ar
e
pe
rf
or
m
ed
on
16
91
ge
ne
s
th
at
ha
ve
w
el
l-
es
ta
bl
is
he
d
as
so
ci
at
io
ns
to
a
se
t
of
12
32
co
nd
it
io
ns
(…
),
an
d
11
m
ed
ic
al
ly
ac
ti
on
ab
le
ge
ne
s
as
so
ci
at
ed
w
it
h
re
sp
on
se
to
16
di
ffe
re
nt
dr
ug
s”
Tr
uG
en
om
e
Te
ch
ni
ca
lS
eq
ue
nc
e
D
at
a
—
“w
ho
le
-g
en
om
e
se
qu
en
ci
ng
da
ta
in
tw
o
fo
rm
at
s:
a
gV
CF
an
d
a
BA
M
”
(h
tt
p:
//
w
w
w
.il
lu
m
in
a.
co
m
/c
lin
ic
al
/i
llu
m
in
a_
cl
in
ic
al
_l
ab
or
at
or
y/
tr
ug
en
om
e-
cl
in
ic
al
-s
eq
ue
nc
in
g-
se
rv
ic
es
.h
tm
l)
“T
ru
G
en
om
e
Cl
in
ic
al
Se
qu
en
ci
ng
Se
rv
ic
es
...
m
us
t
be
or
de
re
d
by
a
lic
en
se
d
ph
ys
ic
ia
n”
(h
tt
p:
//
w
w
w
.il
lu
m
in
a.
co
m
/c
lin
ic
al
/i
llu
m
in
a_
cl
in
ic
al
_l
ab
or
at
or
y/
ho
w
-t
o-
or
de
r.
ht
m
l)
In
fo
rm
ed
Co
ns
en
t
(d
iff
er
en
t
fo
rm
fo
r
ea
ch
te
st
)
G
en
eY
ou
In
,
Ca
na
da
W
ES
:V
it
aS
eq
™
:“
W
it
h
V
it
aS
eq
™
,a
ss
es
s
yo
ur
ri
sk
of
ca
nc
er
,h
ea
rt
di
se
as
e,
au
to
im
m
un
e
or
ne
ur
ol
og
ic
al
di
se
as
es
.”
Pr
eg
na
Se
q™
:“
W
it
h
Pr
eg
na
Se
q™
,g
en
et
ic
te
st
in
g
ca
n
he
lp
yo
u
op
ti
m
iz
e
yo
ur
fe
rt
ili
ty
tr
ea
tm
en
t
an
d
ﬁn
d
ou
t
if
yo
u
an
d
yo
ur
pa
rt
ne
r
ar
e
at
ri
sk
fo
r
pa
ss
in
g
on
pr
ev
en
ta
bl
e
di
se
as
es
.”
(h
tt
ps
:/
/w
w
w
.g
en
ey
ou
in
.c
a/
)
A
he
al
th
ca
re
pr
of
es
si
on
al
is
no
t
re
qu
ir
ed
fo
r
te
st
or
de
ri
ng
(a
lt
ho
ug
h
30
m
in
ut
e
ph
on
e
co
ns
ul
ta
ti
on
is
re
qu
ir
ed
be
fo
re
or
de
ri
ng
)
(h
tt
ps
:/
/w
w
w
.g
en
ey
ou
in
.c
a/
ho
w
-i
t-
w
or
ks
/h
ow
-t
o-
or
de
r/
)
In
fo
rm
ed
Co
ns
en
t,
Te
rm
s
an
d
Co
nd
it
io
ns
G
en
e
By
G
en
e,
U
SA
W
ES
/W
G
S
—
ra
w
da
ta
or
w
it
h
“a
lig
nm
en
ta
nd
va
ri
an
tc
al
lin
g”
(h
tt
ps
:/
/w
w
w
.g
en
eb
yg
en
e.
co
m
/p
ag
es
/r
es
ea
rc
h#
)
or
(o
nl
y
fo
r
W
ES
)
w
it
h
“p
ro
fe
ss
io
na
lR
U
O
[r
es
ea
rc
h
us
e
on
ly
]
in
te
rp
re
ta
ti
on
”
(h
tt
ps
:/
/w
w
w
.g
en
eb
yg
en
e.
co
m
/p
ag
es
/r
es
ea
rc
h?
go
to
=
w
ho
le
-e
xo
m
e-
w
it
h-
in
te
rp
re
ta
ti
on
#
)
Fo
r
Cl
in
ic
al
Te
st
in
g
se
rv
ic
e
a
cl
in
ic
ia
n
or
de
rs
th
e
te
st
(h
tt
ps
:/
/w
w
w
.g
en
eb
yg
en
e.
co
m
/p
ag
es
/g
en
et
ic
s#
ho
w
-t
o-
or
de
r)
;i
nf
or
m
at
io
n
no
t
av
ai
la
bl
e
fo
r
“R
es
ea
rc
h
an
d
Co
ns
um
er
”
se
rv
ic
es
Te
rm
s
an
d
Co
nd
it
io
ns
In
ne
ov
a,
Ca
na
da
W
G
S
—
“s
cr
ee
ni
ng
ri
sk
fa
ct
or
s
an
d
se
ns
it
iv
it
y
to
pa
rt
ic
ul
ar
m
ol
ec
ul
es
w
hi
ch
ca
n
he
lp
a
cl
ie
nt
's
ph
ys
ic
ia
n
re
co
m
m
en
d
sp
ec
iﬁ
c
ch
ec
k-
up
s
as
w
el
la
s
op
ti
m
iz
e
th
e
ad
m
in
is
tr
at
io
n
of
m
ed
ic
at
io
ns
an
d
di
et
s”
(h
tt
p:
//
w
w
w
.in
ne
ov
a.
co
m
/t
ou
t.p
hp
)
“w
e
ac
ce
pt
te
st
re
qu
es
ts
fr
om
lic
en
se
d
m
ed
ic
al
pr
of
es
si
on
al
s
on
ly
”
(h
tt
p:
//
w
w
w
.in
ne
ov
a.
co
m
/t
ou
t.p
hp
)
St
at
em
en
t
of
co
ns
en
t,
D
is
cl
ai
m
er
an
d
pr
iv
ac
y
po
lic
y
24 E. Niemiec, H.C. Howard / Applied & Translational Genomics 8 (2016) 23–30Given that WES/WGS is likely to become increasingly more available
and there is the potential for these services to be coupled with research
activities using consumers' data (http://www.technologyreview.com/
news/540711/inside-illuminas-plans-to-lure-consumers-with-an-app-
store-for-genomes/), the ELSI of DTC genomics are particularly impor-
tant to address now. We therefore studied the websites of companies
advertising WGS and/or WES DTC to shed light on the information
they provide to consumers. More speciﬁcally, we analysed webpage
documents that consumers should sign and/or agree towhen undertak-
ing the test (i.e., depending on the company, sections entitled informed
consent, terms and conditions, statement of consent, disclaimer and pri-
vacy policy; Table 1).We focused on information relevant to storing and
using consumers' data and samples. These issues include: i) purpose
and period of samples and data storage; ii) consumer consent; iii)
data access and sharing; iv) identiﬁability and conﬁdentiality of data;
and v) proprietary claims. Four companies were identiﬁed (circa mid-
2015) which offer and/or advertise WES and/or WGS DTC: Illumina,
Gene by Gene, GeneYouIn, and Inneova. Each stated that they offer
WGS and/or WES, although the scope and focus of data analysis and in-
terpretation varied from providing only raw sequencing data to the di-
agnosis of Mendelian disorders. Moreover, they had different models of
provision (e.g., with or without physician referral; Table 1). We deﬁned
direct-to-consumer genetic/genomic testing as the offer and/or adver-
tisement of testing direct-to-consumers. We considered companies
that required a health care professional to order the WGS or WES ser-
vices also as DTC companies since they were still advertising directly
to consumers, and this can have a signiﬁcant impact on the demand
and ultimate use of a product or service. This is congruent with the
scope of DTC GT given by the UK Human Genetics Commission, which
included situations where “tests are commissioned by the consumer but
where amedical practitioner or health professional is involved in the provi-
sion of the service.” (Human Genetics Commission, 2010).
2. Purpose and period of samples and data storage
Three of the four analysed DTC companies (Illumina, Gene By Gene,
GeneYouIn) stated on their websites that they may use consumers'
data and/or samples for purposes beyondperforming the genetic test or-
dered by the consumer (Table 2). Illumina stated that “leftover specimen
and results may be used by Illumina for purposes of quality control, labora-
tory operations, and laboratory improvement” (http://www.illumina.
com/content/dam/illumina-marketing/documents/clinical/forms/form-
test-req-predisposition.pdf). This suggested that the company performs
internal quality assurance, for which speciﬁc consent is not necessarily
required as long as some conditions are met (e.g., actively informing in-
dividuals of this use; Royal College of Physicians et al., 2011; TheHuman
Tissue Authority, 2004). The period for which the results and specimen
would be stored was not speciﬁed in the analysed document.
Meanwhile, GeneYouIn indicated that it would store the samples for
90 days and that after this period they would be discarded; the compa-
ny did not specify the period for data storage. GeneYouIn also stated ex-
plicitly that it may use consumers'1 data for research, providing a
general description of the type of research on its informed consent page:
“You provide your consent for research inwhichwe analyse your genet-
ic data and phenotype information in order to discover or validate asso-
ciations between certain genetic variations and diseases.”
[https://www.geneyouin.ca/informed-consent]
Gene By Gene indicated in its terms and conditions that it would
store consumer data for 30 days or longer; after this time the data1 The companies GeneYouIn and Gene By Gene use a word “customer” in the analysed
texts. However, as implied in these texts, a customer (meaning a person who buys a test)
is simultaneously a consumer (meaning a user of a test). Therefore, we use theword “con-
sumer” throughout this article, also when referring to the quotations on the webpages of
GeneYouIn and Gene By Gene.
Table 2
Information about the purpose and period of samples and data storage.
Company
name
Quotes concerning purpose and period of samples and data storage Period of storage Information about research activities
Illumina
Informed consenta: “Pursuant to best practices and clinical laboratory
standards, leftover specimen and results may be used by Illumina for
purposes of quality control, laboratory operations, and laboratory
improvement. All such uses [will be de-identiﬁed]*, and in compliance
with applicable law.” *the phrase found only in the informed
consent for TruGenome Predisposition Screen
Not available Not available
GeneYouIn
Informed consenta: “You provide your consent for research in which
we analyze your genetic data and phenotype information in order to
discover or validate associations between certain genetic variations
and diseases. These studies will improve the accuracy of our
predictions for you and other customers. As the number of our
customers grows, our ability to study their combined genetic data and
phenotype information further advances scientiﬁc and medical
research, thus improving health care.” Terms and conditionsa: “Your
genetic data will be stored in Your Account, and you appoint
GeneYouIn as a custodian of your genetic and health data. By accepting
these Terms you agree that your anonymized genetic and health data
can be used for research purposes. (…) All biological samples and DNA
will be destroyed after 90 days following obtaining the test results,
however the information of your genetic code will be stored in Your
Account, and you appoint GeneYouIn as a custodian of your genetic
and health data. By accepting these Terms you agree that your
anonymized genetic and health data can be used for research
purposes.”
Samples — 90 days; data
— not available
Research may be performed on consumers' data
Gene By
Gene
Terms and conditionsa: “Any sample material sent will be used only to
perform the speciﬁcally ordered testing. After testing is complete,
remaining sample material is stored for 180 days, unless otherwise
speciﬁed by regulatory agencies. After 3 months, the sample will be
discarded or de-identiﬁed and retained for in-house laboratory use.
(…)The customer speciﬁcally understands that they will not receive
compensation for any research or commercial products that include or
results from your sample, results, or personal record”.
Data — 30 days or longer;
samples — unclear: at
least 90 or 180 days
Contradictory statements: research will not be performed on
consumers' samples and research may be performed on
consumers' samples and data (inexplicit statement)
Inneova
Disclaimer and privacy policya: “The DNA is used only for the purpose
of predictive genetics testing. Once processed, each DNA sample is
discarded following a secure protocol.”
Samples — discarded
after testing; data and
results — not available
No research on consumers' DNA samples; no information about
research on data
a These denote the speciﬁc documents/sections of websites where the quotes can be found.
25E. Niemiec, H.C. Howard / Applied & Translational Genomics 8 (2016) 23–30might be permanently deleted, however, the consumer could request
storage for a longer period. Regarding the storage of the samples, the
company indicated: “After testing is complete, remaining sample material
is stored for 180 days, unless otherwise speciﬁed by regulatory agencies.”
However, in the following sentence it stated: “After 3 months, the sample
will be discarded or de-identiﬁed and retained for in-house laboratory use”,
making it unclear for what period the samples would be actually stored.
Furthermore, Gene By Gene provided a few statements concerning the
use of samples and data that appear contradictory: “Any sample material
sent will be used only to perform the speciﬁcally ordered testing.” Mean-
while, a few paragraphs below on the same page, it was written:
“After 3 months, the sample will be discarded or de-identiﬁed and retained
for in-house laboratory use.” And: “The customer speciﬁcally understands
that they will not receive compensation for any research or commercial
products that include or results from your sample, results, or personal re-
cord” (https://www.genebygene.com/pages/terms). The last two state-
ments imply that consumers' samples and data may be involved in
research beyond quality assurance, which, without further information,
appears to contradict the ﬁrst statement that samples would be used
only for the ordered testing. This information is ambiguous and
confusing.
The fourth company studied, Inneova, stated that biological samples
would be destroyed after performing the test, but did not describe what
would happen to the data.
The incomplete information provided by the companies regarding
the storage and use of consumers' data and samples is incongruent
with the “Statement of the ESHG (European Society of HumanGenetics)
on direct-to-consumer genetic testing for health-related purposes”
(called further the Statement of the ESHG), which recommends that
companies should “explain what will happen to the sample and the datawhen the testing process is concluded”. Furthermore, in case of research
activities being performed on the consumers' data or samples, the
ESHG (2010) recommends that more detailed information should be
provided: “Informed consent documents for participation in research
should disclose the procedures for storing and disposal of samples and ge-
netic information, the time period and conditions for storing them”
(European Society of Human Genetics, 2010). In addition, DTC GT com-
panies should “have a clearly laid-out plan as to what will happen to the
samples and data should the company be sold or go bankrupt”
(European Society of Human Genetics, 2010). None of the web-
documents/webpages studied from these four companies provided a
description of what will happen in such situations. This echoes results
of a study of DTC GT companies conducted by Zawati et al., 2011, in
which the authors called for “clearer institutional frameworks on the
issue of closure.”
Overall, our results show that two companies indicatedmay perform
research on consumer data and/or samples, while two other companies
did not make reference to research activities. Furthermore, only one
company speciﬁed the period of storage for data, while the period of
storage for samples was stated clearly by two of four companies. None
of the companiesmade reference towhatwould happen if the company
were sold or went bankrupt.
3. Consumer consent
3.1. Consent for services
Based on the websites studied, consumers give their consent for the
services purchased, including agreeing to the information in the afore-
mentioned documents by ordering the test (https://www.geneyouin.ca/
26 E. Niemiec, H.C. Howard / Applied & Translational Genomics 8 (2016) 23–30terms-conditions/; https://www.genebygene.com/pages/terms; http://
www.inneova.info/contenu.php?page=disclaimer.php) or by signing
the form which is sent to the company together with the sample for
analysis (http://www.illumina.com/content/dam/illumina-marketing/
documents/clinical/forms/form-test-req-predisposition.pdf). In the case
of the informed consent from GeneYouIn, it was not made explicit how
exactly consumers provide consent to the testing (e.g., via signature, a
verbal agreement)
“We ask you to provide your informed consent to ensure that, before
purchasing GeneYouIn's genetic testing and consulting services, you
are not only aware of the beneﬁts, but also understand the limitations
and potential risks. Please carefully review the information described
below before you purchase any of our services.”
[https://www.geneyouin.ca/informed-consent/]
The provision of information and the manner of consenting in the
DTC GT context may raise the question of whether consumers have
read and fully understood the information to which they agree and
thuswhether their decision is truly an informed decision. The low read-
ership of sections such as the “terms of service” has already been
discussed in the context of online transactions e.g. when purchasing
software (Maronick, 2014). However, as noted by the Presidential
Commission for the Study of Bioethical Issues (2013), by providing
health information DTC GT companies “interact in both the business
and medical realms, and could ﬁnd themselves subject to the ethical
principles pertinent to business transactions as well as those of medical
care”. Therefore, DTC GT companies, depending on the types of tests
they sell, can be subject to the e-commerce legal framework, as well
as fall within the scope of ethical requirements related to genetic testing
in the clinic context and/or in the realm of research participation. One of
these requirements is to obtain informed consent for testing and re-
search, which has different functions than the terms of service of a con-
sumer contract (Bunnik et al., 2014). The informed consent process
involves providing consumers certain types of information about testing
(e.g. beneﬁts and risks) in an understandable manner. Furthermore, as
explained in the Statement of the ESHG the process of informed consent
should “ensure that individuals understand the disclosed information, are
legally competent and cognitively capable of acting without external pres-
sure, and give their agreement to all the elements involved.” (European
Society of Human Genetics, 2010). It should also protect against invol-
untary testing (Bunnik et al., 2014).3.2. Consent to research
The information about the possibility of performing research on con-
sumers' samples (i.e., for the companies GeneYouIn and Gene by Gene)
was not included on the front pages of the companies' websites or the
main pages including the description of what the companies offer
(Table 1). Therefore, it is not clear whether the consumers have been
aware of the companies' research activities and if they have been genu-
inely consenting to them. Furthermore, the provision of information
about research activities raises concerns about clarity and understand-
ability of this information for consumers, as mentioned earlier. This
type of unclear and non-explicit way of “recruiting” consumers as re-
search participants appears to be in contradiction of the requirement
for informed consent. The importance of informed consent for research
has been articulated by various guidelines and legal documents, for in-
stance the Statement of the ESHG speciﬁes: “If samples or data are to
be used in any research, this should be clear to consumers, and a separate
and unambiguous consent procedure should take place.” (European Socie-
ty of Human Genetics, 2010). This recommendation underlies another
concern about the adequacy of consent for research activities of the
companies, namely the presence of a separate consent procedure. This
practice has been acknowledged and supported as it “enhances autono-
my by drawing the customer's attention to the change in the use of theirsamples and data” (Tobin et al., 2012). Neither of the two companies
that may conduct research and were examined here offered a separate
informed consent form for research. What is even more troubling,
they also did not provide a possibility to opt-out of their potential re-
search activities, which has been criticised as a practice undermining
the autonomy of consumers (Tobin et al., 2012).
3.3. Additional information needed in the consent process
The recommendations for informed consent for research specify that
besides information regarding the destination of the consumers' data
and samples after performing the test, the consent should include addi-
tional elements. For example, the ESHG states:
“Informed consent documents for participation in research should dis-
close the procedures for storing and disposal of samples and genetic in-
formation, the time period and conditions for storing them, inform
participants of the identity of any third parties who may be granted ac-
cess to data or samples, and include also information on the fact that the
researchmay lead to commercialization and patents, on any customers'
rights to commercial beneﬁts and on the property of biological samples
and data.”
[European Society of Human Genetics (2010)]
The Global Alliance for Genomics and Health suggests similar types
of information to be provided in order to respect the responsible sharing
of genomic and health-related data in general, and speciﬁcally to sup-
port the principle of transparency:
“Provide clear information on the purpose, collection, use and exchange
of genomic and health-related data, including, but not limited to: data
transfer to third parties; international transfer of data; terms of access;
duration of data storage; identiﬁability of individuals and data and
limits to anonymity or conﬁdentiality of data; communication of results
to individuals and/or groups; oversight of downstream uses of data;
commercial involvement; proprietary claims; and processes of with-
drawal from data sharing.”
[Knoppers (2014)]
Similarly, the recommendations onWGS issued by the US Presiden-
tial Commission for the Study of Bioethical Issues suggest the presence
of particular elements in informed consent, which also apply to com-
mercial WGS:
“Researchers and clinicians should evaluate and adopt robust and
workable consent processes that allow research participants, patients,
and others to understand who has access to their whole genome se-
quences and other data generated in the course of research, clinical, or
commercial sequencing, and to know how these data might be used in
the future. Consent processes should ascertain participant or patient
preferences at the time the samples are obtained.”
[Presidential Commission for the Study of Bioethical Issues (2012)]
In the remainder of this article we discuss some of the elements that
have been highlighted in the above documents as being important to
communicate to persons undergoing genetic or genomic testing.
4. Data access and sharing
All companies stated that they may grant access to consumers' data
to a third party that is legally authorized or if it is required by law
(e.g., by a court order) (Table 3). Illumina, GeneYouIn and Gene By
Gene also speciﬁed that, with the consumer's consent, they may grant
access to the healthcare provider to whom the test results would be re-
leased. In addition, GeneYouIn indicated that consumers maywithdraw
this type of consent and request deletion of their records. Moreover, the
company speciﬁed that it might share consumers' data with research
Table 3
Information about consumers' data access and sharing.
Company
name
Information on data access and sharing
Illumina Informed consenta: “Illumina keeps test results conﬁdential. Illumina will only release your test results to your healthcare provider, his or her designee, other
healthcare providers involved in your medical care, or to another healthcare provider as directed by you (or a person legally authorized to act on your behalf) in
writing, or otherwise as required or authorized by applicable law.”
(http://www.illumina.com/content/dam/illumina-marketing/documents/clinical/forms/form-test-req-predisposition.pdf)
GeneYouIn Informed consenta: “You authorize GeneYouIn to use and share your anonymized genetic and clinical data with research organizations. If you decide that you do not
want us to share your anonymized genetic and clinical data, please initial the check box next to this bullet point.☐ (…) Please note that GeneYouIn will not disclose
your health information without your explicit consent or a legal order. (…) Through our electronic tools, you can grant your physician or other trusted health care
provider secure access to your report. If at any time you decide to withdraw your consent, you may request deletion of your records.”
(https://www.geneyouin.ca/informed-consent) Terms and conditionsa: “Access to you biological sample and health data by a court-appointed order will be granted
according to the Privacy laws of Canada and Ontario.” (https://www.geneyouin.ca/terms-conditions/)
Gene By Gene Terms and Conditionsa: “Test results will be released only to the ordering clinician or genetic counselor. Gene By Gene, LTD will not release results to a third party
without proper authorization in accordance with the Health Insurance Portability and Accountability Act (HIPSS) of 1996. (…)The customer understands that by
providing any sample, having your sample processed, accessing results, or providing personal information, that the customer acquires no rights in any research or
commercial products or services that may be developed by Gene by Gene, LTD. or its collaborating partners.” (…) “The customer understands that Gene By Gene, LTD. is
not responsible for misuse, mishandling, or misrepresentation of this data by the customer or other third parties who have been given rightful access to the
aforementioned data or materials.” (https://www.genebygene.com/pages/terms)
Inneova Statement of consenta: “I understand that ICL will not disclose my identity, contact details, or test results to third parties (except to its medical, scientiﬁc, and other
service partners, subsidiaries and related business entities, legal advisors, agents, or appointees for the purpose of performing genetic testing or interpretation services,
as well as any associated administrative transactions, as deemed necessary by ICL in the normal course of business under the terms of this Agreement as well as under
its Disclaimer and Privacy Policy). I understand that ICL will be absolved of this responsibility to a limited extent as stated in its Disclaimer and Privacy Policy in the case
of any legal action, court order, or legislation requiring it to do otherwise.” (http://www.inneova.com/contenu.php?page=terms.php)
a These denote the speciﬁc documents/sections of websites where the quotes can be found.
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out of their data sharing by checking a box in the informed consent.
Inneova, although somewhat indirectly, alsomentioned the possibil-
ity of sharing data:
“I understand that ICL will not disclose my identity, contact details, or
test results to third parties (except to its medical, scientiﬁc, and other
service partners, subsidiaries and related business entities, legal advi-
sors, agents, or appointees for the purpose of performing genetic testing
or interpretation services, as well as any associated administrative
transactions, as deemed necessary by ICL in the normal course of busi-
ness under the terms of this Agreement as well as under its Disclaimer
and Privacy Policy).”
[http://www.inneova.com/contenu.php?page=terms.php]
Although the ﬁrst clause statednodisclosure, the list of exceptions in
brackets was long and vague.
Gene By Gene stated that the samples may be “retained for in-house
laboratory use” and did not specify any third parties with which sharing
would happen other than to state that third-party access will only be
givenwith proper “authorization in accordance with the Health Insurance
Portability and Accountability Act”. However, the statement “The custom-
er understands that by providing any sample (…) or providing personal in-
formation, that the customer acquires no rights in any research or
commercial products or services that may be developed by Gene by Gene,
LTD. or its collaborating partners.” (https://www.genebygene.com/
pages/terms) suggests that consumers' data, in some way, may be in-
deed, used by “collaborating partners” and hence shared in some way.
Importantly, the companies did not specify the detailed conditions
(except mentioning “legal authorization”) under which third parties
would gain access to consumer data. Also lacking was information re-
garding whether the transfer of data would be international and infor-
mation about oversight of downstream uses of data, both of which are
elements suggested in the “Framework for responsible sharing of geno-
mic and health-related data” (called further Global Alliance Frame-
work) in order to respect and support transparency in data sharing
(Knoppers, 2014). Similarly, the Presidential Commission for the
Study of Bioethical Issues recommends:
“Funders of whole genome sequencing research; managers of research,
clinical, and commercial databases; and policy makers should maintain
or establish clear policies deﬁning acceptable access to and permissible
uses of whole genome sequence data. These policies should promoteopportunities for models of data sharing by individuals who want to
share their whole genome sequence data with clinicians, researchers,
or others.”
[Presidential Commission for the Study of Bioethical Issues, 2012]
Although both of these documents highlight the importance of shar-
ing data for maximising research potential, and they encourage making
data accessible to researchers, they also stress that sharing should be
conducted in a responsible way. Based on our ﬁndings, this may not
be fully respected by some DTC WGS companies.5. Data security: identiﬁability and conﬁdentiality
All four companies stated that they provide privacy safeguards for
consumers' samples and/or data (Table 4). Illumina stated that con-
sumers need the code provided to their healthcare practitioner in
order to access their results.Meanwhile, GeneYouIn described generally
that it employs “commercially validated and reasonable computational
and organizational safeguards” (https://www.geneyouin.ca/terms-
conditions/). Similarly, Gene By Gene stated that it “implements admin-
istrative, physical and technical safeguards to secure our client's protected
health information as deﬁned by HIPAA” (https://www.genebygene.
com/pages/terms). Furthermore, Illumina, Gene By Gene and Inneova
speciﬁed that the samples and/or data would be de-identiﬁed.
GeneYouIn stated speciﬁcally that consumers' genetic and health data
would be anonymised. The information provided by the companies
seemed, at least to some extent, to fulﬁl the requirement articulated
by the Statement of the ESHG: “companies offering DTC genetic tests
should preserve the customer's privacy, keep their data conﬁdential, inform
them about their security procedures (…).” (European Society of Human
Genetics, 2010). They also concur with the recommendations of the
PCSBI which states that “Accessible whole genome sequence data should
be stripped of traditional identiﬁers whenever possible to inhibit recogni-
tion or re-identiﬁcation” (Presidential Commission for the Study of
Bioethical Issues, 2012). The Global Alliance Framework, additionally,
suggests provision of information about “limits to anonymity or conﬁden-
tiality of data” (Knoppers, 2014). GeneYouIn, Illumina andGene ByGene
stated that there are limitations to the privacy safeguards, whichmay be
breached by, for example, the use of malicious software (Table 4). Yet
information about the possibility of re-identiﬁcation of anonymised ge-
nomic datawasmissing from theweb documents/webpages studied for
Table 4
Information on samples' and data identiﬁability and conﬁdentiality.
Company
name
Samples' and data identiﬁability and conﬁdentiality
Illumina Informed consenta: “You will need to obtain a unique code from your doctor to download your test results. (…) The Internet and wireless services may not be 100%
secure. There is always a risk that you may lose the device or the security on the device may be breached and someone else may then gain access to your test results.
(…) Discrimination Risks. Genetic information could potentially be used as a basis of discrimination. To address concerns regarding possible health insurance and
employment discrimination, many U.S. states and the U.S. government have enacted laws to prohibit genetic discrimination in these circumstances. The laws may not
protect against genetic discrimination in other circumstances such as when applying for life insurance or long-term disability insurance. (...) All such uses [for quality
control, laboratory operations, and laboratory improvement] will be de-identiﬁed.”
(http://www.illumina.com/content/dam/illumina-marketing/documents/clinical/forms/form-test-req-predisposition.pdf)
GeneYouIn Informed consenta: “You authorize GeneYouIn to use and share your anonymized genetic and clinical data (...). The Genetic Information Nondiscrimination Act
(known as GINA) was signed into law in May 2008 in the United Sates. This legislation offers federal protection against discrimination based on an individual's genetic
information in health insurance and employment settings. While there are different laws in place across the globe that prevent companies from discriminating against
people based on race, age, handicaps, and genetic predispositions such laws are not yet fully implemented in Canada.”
(https://www.geneyouin.ca/informed-consent)
Terms and Conditionsa: “We are not responsible for maintaining security and conﬁdentiality of copies of Your Reports stored outside of GeneYouIn's databases. We are
not and cannot be responsible for any personally identiﬁable information about you that you release on your own, or that you request or authorize us to release. (…)
We employ commercially validated and reasonable computational and organizational safeguards against unauthorized disclosure or access to your genetic data or
other personally identiﬁable information about you according to our Privacy & Security Policy. You acknowledge that security safeguards, by their nature, are capable
of circumvention and GeneYouIn does not guarantee that your personal identiﬁable information will not be accessed by unauthorized persons capable of overcoming
such safeguards. In particular, our site may be used to access and transfer information, including personally identiﬁable information about you over the Internet. You
acknowledge and agree that GeneYouIn does not operate or control the Internet and that unauthorized users may use malitious software (viruses, worms, trojan
horses, and other software) to obtain access to personally identiﬁable information about you. GeneYouIn will not be liable to you for any damages in connection with
unauthorized dissemination of your personal information in accordance with this paragraph.” (https://www.geneyouin.ca/terms-conditions/)
Gene By Gene Terms and conditionsa: “After 3 months, the sample will be discarded or de-identiﬁed and retained (...). However, Gene By Gene, LTD implements administrative,
physical and technical safeguards to secure our client's protected health information as deﬁned by HIPAA. (…) Gene By Gene, LTD. will handle all sample specimens in
compliance with all applicable laws and regulations. All data received from the customer and data generated will be created, stored, and transferred according to HIPAA
guidelines. The customer understands that Gene By Gene, LTD. is not responsible for misuse, mishandling, or misrepresentation of this data by the customer or other
third parties who have been given rightful access to the aforementioned data or materials.” (https://www.genebygene.com/pages/terms)
Inneova Disclaimer and privacy policya: “ICL uses a speciﬁc tracking system to identify your sample as soon as it enters our facilities. Molecular biologists in charge of your
sample do not know who the actual sample belongs to, but only see each sample as a number. This tracking number is associated with your name and contact
information only within our secure database, which is not accessible by the lab or anyone outside of our company.”
a These denote the speciﬁc documents/sections of websites where the quotes can be found.
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for genome testing was highlighted by Chow-White et al.:
“(…) the consent form should contain language/disclaimer that privacy
is not absolutely guaranteed. The unstableness of digital networks and
uncertainty of genomic information creates the conditions of privacy
without guarantees. The consent form should (…) provide details of da-
ta release and sharing, including potential public databases where data
could be disseminated and explain the potential of re-identiﬁcation of
anonymized data.”
[Chow-White et al. (2015)]
Moreover, one may argue that using the term “anonymised” is mis-
leading and disingenuous as it has been shown that anonymised geno-
mic data may be re-identiﬁed by linking information from different
databases (Gymrek et al., 2013). Indeed, the term “pseudonomisation”
may be more accurate in the context of genomic data, however it may
be too vague for "lay" consumers to fully understand its meaning.
(Moraia et al., 2015). To clarify this issue, companies should explain to
consumers that although their data will be stripped of personal infor-
mation (de-identiﬁed) there is still a chance of reidentiﬁcation.
The Statement of the ESHG also suggests that “possible conse-
quences related to their [results] disclosure to third parties, such as in-
surance companies and employers, should be discussed” (European
Society of Human Genetics, 2010). Illumina and GeneYouIn stated
that there is a risk of discrimination in case of disclosure of the re-
sults (Table 4). Illumina also mentioned the limitations of legal pro-
tections against discrimination: “The laws may not protect against
genetic discrimination in other circumstances such as when applying for
life insurance or long-term disability insurance.” (http://www.illumina.
com/content/dam/illumina-marketing/documents/clinical/forms/
form-test-req-predisposition.pdf). GeneYouIn and Gene By Gene
also cited the US Genetic Information Nondiscrimination Act
(GINA), which “prohibits health insurers and employers from discrim-
inating based on genetic information” (https://www.genebygene.
com/pages/terms). Furthermore, GeneYouIn mentioned thelimitations of current Canadian law: “While there are different laws
in place across the globe that prevent companies from discriminating
against people based on race, age, handicaps, and genetic predisposi-
tions such laws are not yet fully implemented in Canada.” (https://
www.geneyouin.ca/informed-consent). Gene By Gene outlined pos-
sible consequences of disclosure, including: “misuse, mishandling, or
misrepresentation” (https://www.genebygene.com/pages/terms).
6. Proprietary claims
GeneYouIn and Gene By Gene stated that consumers would not re-
ceive any compensation for being involved in research (Table 5). Gene
By Gene also added that a consumer “will not receive compensation for
(…) commercial products that include or results from [customer's] sample,
results, or personal record.”; and “customer acquires no rights in any re-
search or commercial products or services that may be developed by Gene
by Gene, LTD. or its collaborating partners.” (https://www.genebygene.
com/pages/terms). Meanwhile, GeneYouIn explained that it is a custo-
dian of consumers' genetic and health data; however, it did not appear
to explicitly outline the implications of this fact. The presence of these
elements of information seems to comply with the recommendations
of the Global Alliance Framework (Knoppers, 2014) and the Statement
of the ESHG, which suggests inclusion of “information on the fact that
the researchmay lead to commercialization and patents, on any customers'
rights to commercial beneﬁts and on the property of biological samples and
data.” (European Society of Human Genetics, 2010).
However, the fact that Gene By Gene consumer's sample could actu-
ally be partof a commercial product raises particular ethical concerns in-
cluding whether it is ethically acceptable to sell products that
incorporate consumers' samples potentially without providing any
beneﬁt-sharing for the consumers (National Health and Medical
Research Council, 2011).
In addition, given the concerns about overall adequacy of the
consent process for the companies that may conduct research, we can
question whether consumers are well informed about potential
Table 5
Information on the proprietary claims found on the studied pages of the companies' websites.
Company
name
Proprietary claims
Illumina Not available
GeneYouIn Informed consenta: “You understand that you will not receive any compensation as a result of having your DNA analyzed, Your Genetic Data, or your Phenotype
Information analyzed, or from any other research performed using your Genetic Data or your Phenotype Information.”
(https://www.geneyouin.ca/informed-consent) Terms and conditions:a “(…) you appoint GeneYouIn as a custodian of your genetic and health data.”
(https://www.geneyouin.ca/terms-conditions/)
Gene By Gene Terms and conditionsa: “The customer understands that by providing any sample, having your sample processed, accessing results, or providing personal information,
that the customer acquires no rights in any research or commercial products or services that may be developed by Gene by Gene, LTD. or its collaborating partners. The
customer speciﬁcally understands that they will not receive compensation for any research or commercial products that include or results from your sample, results, or
personal record.” (https://www.genebygene.com/pages/terms)
Inneova Not available
a These denote the speciﬁc documents/sections of websites where the quotes can be found.
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has been reported that at least some of the consumers of the DTC GT
company 23andMewere not aware of thepossibility of commercialising
research results, although the company provided a statement about it in
its online consent form (Allyse, 2013). Importantly, the information
about the potential commercial uses has been shown to be a relevant
factor for deciding about whether to participate in research (Gaskell
et al., 2012). Therefore, this element of information should be provided
to consumers in explicit and clearly understandable form in order to se-
cure their informed choice.
7. Conclusions
Our study of particular sections of companies' websites indicates
that some DTC WGS/WES companies might have conducted research
with consumer data. Moreover, information about these activities, as
well as general information about data and sample storage and speciﬁc
information about data sharing were found to be lacking. For example,
we found multiple instances where disclosures did not comply with
guidelines of the ESHG concerning the offer of DTC GT (European Soci-
ety of Human Genetics, 2010) or with the recommendations outlined
in the “Framework for responsible sharing of genomic and health-
related data” (Knoppers, 2014). This lack of transparency in the pro-
vision of information to consumers could undermine their informed
consent. On the bright side, companies were relatively good at pro-
viding information about general data security. However, they failed
to address the possibility (even if small) of re-identiﬁcation. Finally,
the companies did provide information about proprietary claims and
commercialisation.
We recognize that this study is based on a particular set of web doc-
uments/webpages sampled at a particular moment in time. As such
there is a chance that some of the missing information might have
been found elsewhere on the companies' websites. This being said,
since the documents we chose are speciﬁcally aimed at consumers to
read and agree to, we would argue that the necessary information for
data and sample storage, secondary use, and potential data or sample
sharing should be included in these documents.
Some of the ethical concerns regarding the research practices of DTC
WGS companies discussed herein have been raised previously (Gibson
and Copenhaver, 2010; Howard et al., 2015). Furthermore, earlier this
year, it was reported that the DTC GT company 23andMe together
with the biotechnology company Genentech was to perform WGS on
23andMe consumers' samples, raising concerns about informed con-
sent, data privacy, management of incidental ﬁndings and availability
of the data to other researchers (Adam and Friedman, 2015). Although
the ethical and legal study of DTC GT companies has been ongoing for
almost a decade, it would appear that some of the ethical concerns
about these companies and their research activities have not been
resolved, but rather ampliﬁed as new sequencing technologies are
implemented. Meanwhile, one of the DTC GT companies, 23andMe,
has been remarkably successful in recruiting research participants(http://www.forbes.com/sites/matthewherper/2015/10/14/23andme-
prepares-a-comeback-raising-115-million-at-a-1-1-billion-valuation/),
thus gaining a signiﬁcant share of the general community of biobank re-
search and in doing so, potentially inﬂuencing the public perception of
research. Noncompliance with ethical standards or recommendations
by well-known companies could have signiﬁcant negative implications
for biomedical research in general. Therefore, it is particularly important
to examine the behaviour of DTC GT companies and to promote the
awareness and adherence to the ethical standards currently accepted
and/or aspired to by the research community. In order to achieve this,
it would be constructive to have the community of commercial compa-
nies weigh in on the development of best practice guidelines for the
commercial realm along with relevant stakeholders such as consumers,
patients and health care professionals.
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